Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

What is this patent about?

’474 is related to the field of monoclonal antibody production and pharmaceutical chemistry, specifically focusing on the purification and characterization of HER2 antibodies. In the production of complex biologics, antibodies often exist as a mixture of a primary molecular form and various structural variants that arise during cell culture or processing. This patent addresses the specific challenge of managing charge heterogeneity, where certain antibody variants exhibit a more acidic profile than the intended main species.

The underlying idea behind ’474 is that while a therapeutic antibody composition inevitably contains molecular variants, these variants can be identified, quantified, and maintained within specific limits to ensure product consistency. The inventor’s key insight is that for the HER2-binding antibody Pertuzumab, the presence of specific acidic variants—including those that are glycated, deamidated, or structurally altered—does not negatively impact the drug's performance. By demonstrating that these variants possess nearly identical pharmacokinetics to the main species, the invention establishes a defined chemical profile for a safe and effective pharmaceutical formulation.

The claims of ’474 focus on a composition containing a main species HER2 antibody, defined by the specific amino acid sequences of Pertuzumab (SEQ ID Nos. 3 and 4), alongside a specific suite of acidic variants. These variants must include disulfide reduced and non-reducible forms, and in broader embodiments, also include glycated, deamidated, and sialylated versions. Crucially, the independent claims require that these acidic variants collectively constitute less than 25% of the total antibody composition.

In practice, the invention is implemented by monitoring the molecular distribution of the antibody using cation exchange chromatography, which separates the proteins based on their charge. The acidic variants are those that elute earlier than the main peak. The process involves preparing the antibody in a cell culture, evaluating the variant levels through analytical methods like mass spectrometry or capillary electrophoresis, and confirming that the variant threshold is not exceeded before combining the mixture with a pharmaceutically acceptable carrier.

This approach differs from prior art by providing a precise characterization of the Pertuzumab-specific variant profile rather than just general antibody mixtures. While previous methods might have viewed these variants as impurities to be eliminated, ’474 recognizes them as bioequivalent components that can remain in the final product. By proving that the acidic variants and the main species have essentially the same behavior within the body, the patent enables a more robust and predictable manufacturing process for HER2-positive cancer treatments.